Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because Wave is better suited to quickly advance a rare disease therapy.
Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because Wave is better suited to quickly advance a rare disease therapy.
